On 25 April, Bon-Ton Stores Inc. (NASDAQ:BONT) shares advanced 1.28% and was closed at $2.38. BONT EPS growth in last 5 year was -35.60%. Bon-Ton Stores Inc. (NASDAQ:BONT) year to date (YTD) performance is 13.33%.
Bon-Ton Stores Inc. (NASDAQ:BONT) announced its Board of Directors has unanimously elected Paul E. Rigby to its Board, effective immediately. Mr. Rigby will join the Audit Committee.
Masonite International Corporation (NYSE:DOOR) shares fell -0.06% in last trading session and ended the day at $69.46. DOOR Gross Margin is 18.70% and its has a return on assets of -3.10%. Masonite International Corporation (NYSE:DOOR) quarterly performance is 26.80%.
Masonite International Corporation (NYSE:DOOR) announced a change to its reportable segments, effective for the quarter ending April 3, 2016, to align with changes in how the Company manages the business, reviews operating performance and allocates resources as a result of the deconsolidation of South Africa and other internal reporting changes. The Company will begin to report results under the new reportable segments with the filing of its Quarterly Report on Form 10-Q for the quarter ending April 3, 2016.
Intrexon Corporation (NYSE:XON) caters to the Healthcare space. It has a net profit margin of -48.70% and weekly performance is -24.82%. On the last day of trading company shares ended up at $27.81. Intrexon Corporation (NYSE:XON) distance from 50-day simple moving average (SMA50) is -19.40%.
On 13 April, Intrexon Corporation (NYSE:XON) announced it has entered into Exclusive Channel Collaborations (ECC) with two startups backed by the Harvest Intrexon Enterprise Fund, sponsored by Harvest Capital Strategies, LLC.
Boston Scientific Corporation (NYSE:BSX) shares decreased -0.10% in last trading session and ended the day at $19.74. BSX Gross Margin is 71.40% and its has a return on assets of -1.40%. Boston Scientific Corporation (NYSE:BSX) quarterly performance is 12.61%.
Boston Scientific Corporation (NYSE:BSX) and Edwards Lifesciences ($EW) have been scuffling over patents for heart valve replacement devices in Europe. Now, the legal battle is expanding to the U.S. as Boston Scientific vies for more market share.
Puma Biotechnology, Inc. (NYSE:PBYI) caters to the Healthcare space. Its weekly performance is -0.15%. On the last day of trading company shares ended up at $32.70. Puma Biotechnology, Inc. (NYSE:PBYI) distance from 50-day simple moving average (SMA50) is -16.12%.
Puma Biotechnology, Inc. (NYSE:PBYI), a biopharmaceutical company, announced that its drug candidate neratinib was highlighted in three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016. The AACR Annual Meeting was held at the Ernest N. Morial Convention Center in New Orleans from April 16 to April 20.
Leave a Reply